Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amarpal Chana

Interventional Cardiology Laguna Hills, CA Medical Doctor

NPI 1669763447 CMS profile 121430

24022 Calle De La Plata, Suite 500, Laguna Hills, CA 92653

Open in the dashboard

General payments

$270

11 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amarpal Chana of Laguna Hills, CA is reported in the CMS Open Payments database as having received $270 across 11 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 5th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $208 8
2023 General $17 1
2020 General $22 1
2019 General $23 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amarpal Chana
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Amarpal Chana were reported at $208. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Amarpal Chana Interventional Cardiology median Middle half National median
2019 $23 $1,097 $329–$3,048 $163
2020 $22 $473 $161–$1,480 $114
2021 $0 $677 $233–$1,827 $132
2022 $0 $978 $333–$2,724 $149
2023 $17 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $208 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $84 3 payments
  2. E.R. Squibb & Sons, L.L.C. $67 3 payments
  3. Cleerly, Inc. $37 1 payment
  4. Amgen Inc. $23 1 payment
  5. Cardiovascular Systems Inc. $22 1 payment
  6. BSN Medical Inc $20 1 payment
  7. iRhythm Technologies, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $270 11 payments
Products named General payments · program years 2019–2025
  1. LEQVIO $84 3 payments
  2. CAMZYOS $49 2 payments
  3. Cleerly Ischemia $37 1 payment
  4. Cleerly Labs $37 1 payment
  5. Repatha $23 1 payment
  6. Corlanor $23 1 payment
  7. Coronary Orbital Atherectomy System $22 1 payment
  8. JOBST RELAX $20 1 payment
  9. ELIQUIS $17 1 payment
  10. ZIO XT Patch $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,260

Median for Cardiology: 2,533

Drug cost

$421,636

Median for Cardiology: $485,213

Branded share of claims

26.5%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 256 $223,816
Xarelto Rivaroxaban Brand 78 $88,083
Brilinta Ticagrelor Brand 63 $48,285
Entresto Sacubitril/Valsartan Brand 24 $32,039
Repatha Sureclick Evolocumab Brand 13 $10,534
Atorvastatin Calcium Generic 476 $4,125
Metoprolol Succinate Generic 204 $3,206
Rosuvastatin Calcium Generic 65 $1,150
Losartan Potassium Generic 134 $1,094
Clopidogrel Clopidogrel Bisulfate Brand 79 $994

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$11,637

Medicare's payments for the services billed

Medicare patients

81

Average age 73

Services billed

162

43 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Ischemic heart disease 37%
Arthritis 37%
Chronic kidney disease 30%
Atrial fibrillation 28%
Heart failure 26%
Osteoporosis 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

11 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record